Inhibrx Biosciences, Inc. (INBX) Financial Ratios
10 years of historical data (2016–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
241.27
↑+393% vs avg
5yr avg: 48.92
30Y Low1.7·High153.1
ROE
↓
-197.8%
↑-218% vs avg
5yr avg: 168.4%
30Y Low-475%·High-100%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
INBX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Inhibrx Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.8B | $1.2B | $223M | $1.8B | $988M | $1.7B | $833M | — | — | — | — |
| Enterprise Value | $1.8B | $1.2B | $78M | $1.7B | $921M | $1.6B | $742M | — | — | — | — |
| P/E Ratio → | -13.77 | — | 0.13 | — | — | — | — | — | — | — | — |
| P/S Ratio | 1396.35 | 941.13 | 1114.64 | 994.97 | 450.85 | 232.97 | 65.03 | — | — | — | — |
| P/B Ratio | 241.27 | 153.07 | 1.67 | 41.17 | 17.02 | 31.69 | 11.04 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
INBX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 927.90 | 391.90 | 957.31 | 420.39 | 224.67 | 57.90 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | 0.05 | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
INBX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Inhibrx Biosciences, Inc. earns an operating margin of -10386.5%. Operating margins have expanded from -12178.9% to -10386.5% over the past 3 years, signaling improving operational efficiency. A negative ROE of -197.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | -1042.5% | 33.8% | -4926.7% | 62.3% | -473.8% | -426.9% | -346.1% | -220.9% | -154.9% |
| Operating Margin | -10386.5% | -10386.5% | -165724.0% | -12178.9% | -5890.4% | -1074.6% | -526.6% | -480.7% | -393.5% | -248.2% | -182.2% |
| Net Profit Margin | -10773.5% | -10773.5% | 843786.0% | -13408.9% | -6625.3% | -1147.6% | -590.5% | -565.3% | -415.5% | -244.6% | -124.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -197.8% | -197.8% | 1905.9% | -475.3% | -263.0% | -127.9% | -100.2% | — | — | — | -667.4% |
| ROA | -85.6% | -85.6% | 690.7% | -80.6% | -65.8% | -55.6% | -88.9% | -281.9% | -228.9% | -101.0% | -38.9% |
| ROIC | — | — | — | — | — | — | — | — | — | — | -6901.1% |
| ROCE | -106.9% | -106.9% | -169.3% | -85.2% | -66.0% | -63.7% | -114.1% | -738.5% | -2773.8% | -162.3% | -76.0% |
INBX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $124M exceeds total debt of $107M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 13.39 | 13.39 | 0.06 | 4.83 | 3.57 | 1.38 | 0.50 | — | — | — | 15.27 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -2.15 | -1.08 | -1.56 | -1.15 | -1.13 | -1.21 | — | — | — | -0.89 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -24.57 | -6.89 | -8.02 | -14.68 | -6.24 | -7.64 | -19.94 | -9.28 | — |
Net cash position: cash ($124M) exceeds total debt ($107M)
INBX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Inhibrx Biosciences, Inc.'s current ratio of 3.93x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 5.25x to 3.93x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.93 | 3.93 | 3.94 | 5.25 | 10.17 | 6.20 | 4.21 | 0.76 | 0.35 | 1.73 | 3.87 |
| Quick Ratio | 3.93 | 3.93 | 3.94 | 5.25 | 10.17 | 6.23 | 8.33 | 0.60 | 0.21 | 1.62 | 3.87 |
| Cash Ratio | 3.68 | 3.68 | 3.75 | 4.94 | 9.93 | 5.85 | 4.10 | 0.56 | 0.13 | 1.51 | 3.79 |
| Asset Turnover | — | 0.01 | 0.00 | 0.01 | 0.01 | 0.05 | 0.09 | 0.34 | 0.75 | 0.46 | 0.31 |
| Inventory Turnover | — | — | — | — | — | — | — | 14.94 | 14.48 | 25.54 | — |
| Days Sales Outstanding | — | 49.70 | 766.50 | 157.76 | 42.79 | 44.98 | 17.53 | 17.58 | 33.58 | 31.95 | — |
INBX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Inhibrx Biosciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 757.0% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $15M | $14M | $47M | $40M | $38M | $25M | $37M | $27M | $29M | $37M |
Peer Comparison
Compare INBX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 INBXYou | $2B | -13.8 | — | — | — | -10386.5% | -197.8% | — | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 ARQT | $3B | -158.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 TGTX | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 ALKS | $6B | 24.8 | 17.3 | 12.3 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
 XNCR | $903M | -9.9 | — | — | 91.6% | -141.4% | -14.0% | -16.3% | — |
 MGNX | $186M | -2.5 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
See INBX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INBX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INBX vs IMVT
Side-by-side business, growth, and profitability comparison vs Immunovant, Inc..
Start ComparisonINBX — Frequently Asked Questions
Quick answers to the most common questions about buying INBX stock.
What is Inhibrx Biosciences, Inc.'s P/E ratio?
Inhibrx Biosciences, Inc.'s current P/E ratio is -13.8x. The historical average is 0.1x.
What is Inhibrx Biosciences, Inc.'s ROE?
Inhibrx Biosciences, Inc.'s return on equity (ROE) is -197.8%. The historical average is -232.9%.
Is INBX stock overvalued?
Based on historical data, Inhibrx Biosciences, Inc. is trading at a P/E of -13.8x. Compare with industry peers and growth rates for a complete picture.
What are Inhibrx Biosciences, Inc.'s profit margins?
Inhibrx Biosciences, Inc. has -10386.5% operating margin.